49 related articles for article (PubMed ID: 29949330)
1. Protective effect of Xuebijing injection on myocardial injury in patients with sepsis: a randomized clinical trial.
Zhang H; Wei L; Zhao G; Liu S; Zhang Z; Zhang J; Yang Y
J Tradit Chin Med; 2016 Dec; 36(6):706-10. PubMed ID: 29949330
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologically significant constituents collectively responsible for anti-sepsis action of XueBiJing, a Chinese herb-based intravenous formulation.
Cheng C; Ren C; Li MZ; Liu YH; Yao RQ; Yu Y; Yu X; Wang JL; Wang LX; Leng YC; Zhang H; Du FF; Dong N; Wang FQ; Wu Y; Xu F; Zhu XM; Zhang GP; Dong K; Liu S; Yao XQ; Li C; Yao YM
Acta Pharmacol Sin; 2024 May; 45(5):1077-1092. PubMed ID: 38267547
[TBL] [Abstract][Full Text] [Related]
3. [Scepticism about a Chinese herbal mixture for sepsis].
Pickkers P
Ned Tijdschr Geneeskd; 2023 Sep; 167():. PubMed ID: 37823871
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the effect of continuous blood purification combined with xuebijing in the treatment of sepsis and its impact on inflammatory factors and hemodynamic indicators in patients.
Guo C; Huang A; Yang S; Cheng W; Zhu J
Panminerva Med; 2024 May; ():. PubMed ID: 38804069
[No Abstract] [Full Text] [Related]
5. XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.
Song Y; Yao C; Yao Y; Han H; Zhao X; Yu K; Liu L; Xu Y; Liu Z; Zhou Q; Wang Y; Ma Z; Zheng Y; Wu D; Tang Z; Zhang M; Pan S; Chai Y; Song Y; Zhang J; Pan L; Liu Y; Yu H; Yu X; Zhang H; Wang X; Du Z; Wan X; Tang Y; Tian Y; Zhu Y; Wang H; Yan X; Liu Z; Zhang B; Zhong N; Shang H; Bai C
Crit Care Med; 2019 Sep; 47(9):e735-e743. PubMed ID: 31162191
[TBL] [Abstract][Full Text] [Related]
6. The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.
Ma Q; Qiu M; Zhou H; Chen J; Yang X; Deng Z; Chen L; Zhou J; Liao Y; Chen Q; Zheng Q; Cai L; Shen L; Yang Z
Pharmacol Res; 2020 Oct; 160():105073. PubMed ID: 32653650
[No Abstract] [Full Text] [Related]
7. The current evidence for the treatment of sepsis with Xuebijing injection: Bioactive constituents, findings of clinical studies and potential mechanisms.
Li C; Wang P; Li M; Zheng R; Chen S; Liu S; Feng Z; Yao Y; Shang H
J Ethnopharmacol; 2021 Jan; 265():113301. PubMed ID: 32860891
[TBL] [Abstract][Full Text] [Related]
8. GC/MS-based metabonomics approach reveals effects of Xuebijing injection in CLP induced septic rats.
Jiang Y; Zou L; Liu S; Liu X; Chen F; Liu X; Zhu Y
Biomed Pharmacother; 2019 Sep; 117():109163. PubMed ID: 31238257
[TBL] [Abstract][Full Text] [Related]
9. Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With Sepsis: The EXIT-SEP Randomized Clinical Trial.
Liu S; Yao C; Xie J; Liu H; Wang H; Lin Z; Qin B; Wang D; Lu W; Ma X; Liu Y; Liu L; Zhang C; Xu L; Zheng R; Zhou F; Liu Z; Zhang G; Zhou L; Liu J; Fei A; Zhang G; Zhu Y; Qian K; Wang R; Liang Y; Duan M; Wu D; Sun R; Wang Y; Zhang X; Cao Q; Yang M; Jin M; Song Y; Huang L; Zhou F; Chen D; Liang Q; Qian C; Tang Z; Zhang Z; Feng Q; Peng Z; Sun R; Song Z; Sun Y; Chai Y; Zhou L; Cheng C; Li L; Yan X; Zhang J; Huang Y; Guo F; Li C; Yang Y; Shang H; Qiu H;
JAMA Intern Med; 2023 Jul; 183(7):647-655. PubMed ID: 37126332
[TBL] [Abstract][Full Text] [Related]
10. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021.
Evans L; Rhodes A; Alhazzani W; Antonelli M; Coopersmith CM; French C; Machado FR; Mcintyre L; Ostermann M; Prescott HC; Schorr C; Simpson S; Wiersinga WJ; Alshamsi F; Angus DC; Arabi Y; Azevedo L; Beale R; Beilman G; Belley-Cote E; Burry L; Cecconi M; Centofanti J; Coz Yataco A; De Waele J; Dellinger RP; Doi K; Du B; Estenssoro E; Ferrer R; Gomersall C; Hodgson C; Møller MH; Iwashyna T; Jacob S; Kleinpell R; Klompas M; Koh Y; Kumar A; Kwizera A; Lobo S; Masur H; McGloughlin S; Mehta S; Mehta Y; Mer M; Nunnally M; Oczkowski S; Osborn T; Papathanassoglou E; Perner A; Puskarich M; Roberts J; Schweickert W; Seckel M; Sevransky J; Sprung CL; Welte T; Zimmerman J; Levy M
Intensive Care Med; 2021 Nov; 47(11):1181-1247. PubMed ID: 34599691
[No Abstract] [Full Text] [Related]
11. High degree of pharmacokinetic compatibility exists between the five-herb medicine XueBiJing and antibiotics comedicated in sepsis care.
Li J; Olaleye OE; Yu X; Jia W; Yang J; Lu C; Liu S; Yu J; Duan X; Wang Y; Dong K; He R; Cheng C; Li C
Acta Pharm Sin B; 2019 Sep; 9(5):1035-1049. PubMed ID: 31649852
[TBL] [Abstract][Full Text] [Related]
12. A real-world study on adverse drug reactions to Xuebijing injection: hospital intensive monitoring based on 93 hospitals (31,913 cases).
Zheng R; Wang H; Liu Z; Wang X; Li J; Lei X; Fan Y; Liu S; Feng Z; Shang H
Ann Transl Med; 2019 Mar; 7(6):117. PubMed ID: 31032272
[TBL] [Abstract][Full Text] [Related]
13. The immunology of sepsis.
van der Poll T; Shankar-Hari M; Wiersinga WJ
Immunity; 2021 Nov; 54(11):2450-2464. PubMed ID: 34758337
[TBL] [Abstract][Full Text] [Related]
14. The Epidemiology of Sepsis in Chinese ICUs: A National Cross-Sectional Survey.
Xie J; Wang H; Kang Y; Zhou L; Liu Z; Qin B; Ma X; Cao X; Chen D; Lu W; Yao C; Yu K; Yao X; Shang H; Qiu H; Yang Y;
Crit Care Med; 2020 Mar; 48(3):e209-e218. PubMed ID: 31804299
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Xuebijing Injection for Sepsis (EXIT-SEP): protocol for a randomised controlled trial.
Liu S; Yao C; Zhang J; Yang Y; Qiu H;
BMJ Open; 2019 Aug; 9(8):e028664. PubMed ID: 31467049
[TBL] [Abstract][Full Text] [Related]
16. Population enrichment for critical care trials: phenotypes and differential outcomes.
Shankar-Hari M; Rubenfeld GD
Curr Opin Crit Care; 2019 Oct; 25(5):489-497. PubMed ID: 31335383
[TBL] [Abstract][Full Text] [Related]
17. Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial.
Vincent JL; Francois B; Zabolotskikh I; Daga MK; Lascarrou JB; Kirov MY; Pettilä V; Wittebole X; Meziani F; Mercier E; Lobo SM; Barie PS; Crowther M; Esmon CT; Fareed J; Gando S; Gorelick KJ; Levi M; Mira JP; Opal SM; Parrillo J; Russell JA; Saito H; Tsuruta K; Sakai T; Fineberg D;
JAMA; 2019 May; 321(20):1993-2002. PubMed ID: 31104069
[TBL] [Abstract][Full Text] [Related]
18. Intravenous Vitamin C in Adults with Sepsis in the Intensive Care Unit.
Lamontagne F; Masse MH; Menard J; Sprague S; Pinto R; Heyland DK; Cook DJ; Battista MC; Day AG; Guyatt GH; Kanji S; Parke R; McGuinness SP; Tirupakuzhi Vijayaraghavan BK; Annane D; Cohen D; Arabi YM; Bolduc B; Marinoff N; Rochwerg B; Millen T; Meade MO; Hand L; Watpool I; Porteous R; Young PJ; D'Aragon F; Belley-Cote EP; Carbonneau E; Clarke F; Maslove DM; Hunt M; Chassé M; Lebrasseur M; Lauzier F; Mehta S; Quiroz-Martinez H; Rewa OG; Charbonney E; Seely AJE; Kutsogiannis DJ; LeBlanc R; Mekontso-Dessap A; Mele TS; Turgeon AF; Wood G; Kohli SS; Shahin J; Twardowski P; Adhikari NKJ;
N Engl J Med; 2022 Jun; 386(25):2387-2398. PubMed ID: 35704292
[TBL] [Abstract][Full Text] [Related]
19. Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial.
Liu Y; Zhang C; Li C; Bai C; Shang H
Clin Interv Aging; 2020; 15():2109-2115. PubMed ID: 33204076
[TBL] [Abstract][Full Text] [Related]
20. Xuebijing injection protects sepsis induced myocardial injury by mediating TLR4/NF-κB/IKKα and JAK2/STAT3 signaling pathways.
Kang XF; Lu XL; Bi CF; Hu XD; Li Y; Li JK; Yang LS; Liu J; Ma L; Zhang JF
Aging (Albany NY); 2023 Aug; 15(16):8501-8517. PubMed ID: 37650558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
